Literature DB >> 2706880

Influence of renal function on the pharmacokinetics and cardiovascular effects of nisoldipine after single and multiple dosing.

J van Harten1, J Burggraaf, P van Brummelen, D D Breimer.   

Abstract

The pharmacokinetics and cardiovascular effects of the calcium entry blocker nisoldipine (10 mg twice daily) were studied in 6 patients with renal failure (creatinine clearance 23 +/- 9 ml/min) and 6 healthy control subjects after a single dose and 1 week of oral administration. No significant differences in elimination half-life, area under the concentration/time curve, peak plasma drug concentration and time to reach that peak were observed between renal patients and control subjects, and between single-dose and short term administration. The decrease in systolic blood pressure and increase in heart rate were similar in both groups, but the decrease in diastolic blood pressure was more pronounced in the patients. This can be explained by increased haemodynamic sensitivity for nisoldipine. Adverse effects were mainly restricted to the first day of administration.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706880     DOI: 10.2165/00003088-198916010-00004

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  29 in total

1.  Gas chromatographic determination of nisoldipine and one of its metabolites in plasma.

Authors:  J Van Harten; M T Lodewijks; J W Guyt-Scholten; P Van Brummelen; D D Breimer
Journal:  J Chromatogr       Date:  1987-12-25

2.  Diagnostic value of intact parathyroid hormone measurement.

Authors:  A C Nieuwenhuijzen Kruseman; M Frölich; S T Walma; R M Valentijn
Journal:  Neth J Med       Date:  1987-08       Impact factor: 1.422

3.  Pharmacokinetics and hemodynamic effects of nisoldipine and its interaction with cimetidine.

Authors:  J van Harten; P van Brummelen; M T Lodewijks; M Danhof; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1988-03       Impact factor: 6.875

4.  beta blockade with pindolol: differential cardiac and renal effects despite similar plasma kinetics in normal and uremic man.

Authors:  R L Galeazzi; M Gugger; P Weidmann
Journal:  Kidney Int       Date:  1979-06       Impact factor: 10.612

Review 5.  Drug dosage in renal disease.

Authors:  L Dettli
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

6.  Intrinsic and reflex actions of verapamil and nifedipine: assessment in normal subjects by noninvasive techniques and autonomic blockade.

Authors:  H C Stern; J H Matthews; G G Belz
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Nitrendipine kinetics in normal and impaired renal function.

Authors:  G R Aronoff; R S Sloan
Journal:  Clin Pharmacol Ther       Date:  1985-08       Impact factor: 6.875

8.  Clinical pharmacokinetics of nimodipine in normal and impaired renal function.

Authors:  W Kirch; K D Rämsch; U Dührsen; E E Ohnhaus
Journal:  Int J Clin Pharmacol Res       Date:  1984

9.  Improvement in exercise performance with nisoldipine, a new second-generation calcium blocker, in stable angina patients.

Authors:  L M Lopez; M R Rubin; J P Holland; J L Mehta
Journal:  Am Heart J       Date:  1985-11       Impact factor: 4.749

10.  Pharmacokinetics of nisoldipine in renal dysfunction.

Authors:  J Boelaert; Y Valcke; H Dammekens; G De Vriese; G Ahr; M Schurgers; R Daneels; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

View more
  7 in total

1.  Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function.

Authors:  P A Soons; T Ankermann; D D Breimer; W Kirch
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

Review 4.  Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  H A Friedel; E M Sorkin
Journal:  Drugs       Date:  1988-12       Impact factor: 9.546

Review 5.  Clinical pharmacokinetics of vasodilators. Part I.

Authors:  R Kirsten; K Nelson; D Kirsten; B Heintz
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

Review 6.  Drug administration in patients with renal insufficiency. Minimising renal and extrarenal toxicity.

Authors:  G R Matzke; R F Frye
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

Review 7.  Clinical pharmacokinetics of nisoldipine coat-core.

Authors:  R Heinig
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 5.577

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.